<DOC>
	<DOCNO>NCT00187304</DOCNO>
	<brief_summary>The primary objective study compare two different regimen therapy , AVK ASA ( aspirin ) , early postoperative period aortic valve replacement SJM Epic™ SJM Epic™ Supra Porcine Bioprosthetic Heart Valve establish adverse event free survival rate 3 month post intervention follow-up 2 group ( special focus thromboembolic event bleeding ) .</brief_summary>
	<brief_title>ACTION - Anticoagulation Treatment Influence Post-operative Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>1 . Patient require , first time , isolate aortic valve replacement ( pacemaker insertion allow ) 2 . Patient ( legal guardian ) sign study specific inform consent form agree data collection followup requirement . 3 . Patient legal age host country 4 . The patient sinus rhythm implantation 1 . Patient already prosthetic valve , valve replaced time . 2 . Patient require double valve implantation 3 . Patient require concomitant CABG 4 . Patients require intra aortic balloon pump intervention 5 . Patient medical condition contraindicates implantation SJM Epic and/or SJM Epic Supra Porcine Bioprosthetic Heart Valve ( e.g . patient dialysis ) 6 . Patient require ASA AVK therapy , i.e . suitable randomization 7 . Patient pregnant nursing . 8 . Patient affect active endocarditis . 9 . Patient affect aortic dissection . 10 . Patient history cerebral ischemia 11 . Patient affect coagulopathy , history GI bleeding increase bleed risk 12 . Patient affect peripheral vascular disease require treatment 13 . Patient previous chronic anticoagulation therapy 14 . Patient allergic ASA and/or AVK</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>